


Alabama Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Alabama from January 2017 through December 2017.

Key Alabama Findings



Rejection Rate:

35%



Appeals Rate:

21%



Final Rejections:

1,743

Of health plans that received at least 100 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- BCBS Alabama **48%**
- Express Scripts **37%**
- CVS Health **45%**
- Cigna Healthcare **33%**

The following had **the lowest rates of rejection:**

- Humana Health Plan **19%**
- State Employees Health Insurance SEHIP **8%**



The following table details claims data for the Alabama managed care organizations that received at least 100 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
BCBS AL	48%	1,089	525
CVS Health	45%	286	128
Express Scripts	37%	197	72
Cigna Healthcare	33%	230	77
Viva Health	26%	175	45
United Health Group	24%	952	233
Aetna	22%	148	32
Humana Health Plan	19%	650	123
State Employees Health Insurance Plan SEHIP	8%	201	16

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

